Targeting the Immune System in Multiple Sclerosis: Current Concepts and Update on New Therapies– Our understanding of alterations that can occur in the immune system in patients with multiple sclerosis (MS) continues to rapidly evolve. This has led to the identification of new therapeutic targets and strategies for medical management. Although parenterally administered disease-modifying therapies such as interferons, glatiramer acetate and natalizumab have been the primary treatment options over the last two decades, the first oral medication for relapsing forms of MS was approved in 2010 and several additional oral agents are in late stages of clinical development. In addition, new monoclonal antibodies that target immune system components are expected to become available in the near future. This educational program, features two expert faculty who specialize in MS and provides neurologists and their treatment teams the opportunity to learn about the latest insights into the immunopathology underlying MS and how recent developments in the medical management of patients with MS may impact contemporary neurology practice.
Describe key pathways involved in the immunopathogenesis underlying multiple sclerosis
Identify potential targets for therapeutic intervention in patients with multiple sclerosis, based on immune dysfunction.
Review the efficacy and safety of new and emerging therapies for multiple sclerosis, including oral therapies and monoclonal antibodies.
1.0 Free CEUs for Nurse Practitioners which includes 0.5 Hours of Pharmacology
This course also offers Free CEUs for Physicians, PAs, Pharmacists and Nurses